HEPATOCELLULAR CARCINOMA (HCC)

This study tests a procedure called irreversible electroporation (IRE) to treat liver cancer that hasn't spread. IRE uses short electric pulses to destroy tumor cells without cutting or heating the liver. The study will enroll 50 adults with preserved liver function and up to 3 s…

This study tests whether adding Babao Dan Capsule (a traditional Chinese medicine) to standard antiviral treatment can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis who are at high risk. About 1,034 adults aged 18-65 with a specific trad…

This study tests a personalized approach for people with advanced liver cancer that cannot be removed by surgery. Researchers will analyze the tumor's metabolism (how it uses fat for energy) to assign each patient to a specific treatment combination. The goal is to see if this ta…

This study compares two treatments for small liver cancer: surgery and a precise type of radiation called SBRT. About 312 adults with a single tumor 5 cm or smaller will be randomly assigned to one of the two treatments. The main goal is to see which approach helps people live lo…

This early-phase trial tests a new treatment called Meta10-GPC3 for people with advanced liver cancer that cannot be removed by surgery. The treatment uses specially modified immune cells (CAR-T cells) designed to find and attack cancer cells. The main goal is to check safety, an…

This phase 3 trial tests whether adding TPST-1120 to standard immunotherapy and anti-angiogenesis drugs helps people with advanced liver cancer live longer. About 740 adults whose cancer cannot be surgically removed or has spread will be randomly assigned to receive either the tr…

This study tests a new approach for people with advanced liver cancer whose initial targeted-immunotherapy stopped working. Participants will either receive their original treatment plus a fecal transplant and specialized radiotherapy, or switch to a standard second-line therapy.…

This study looks at whether giving a bone-strengthening drug (denosumab) early, along with standard cancer therapy, can prevent bone problems like fractures or spinal cord compression in people with liver cancer that has spread to the bones. About 50 adults will be randomly assig…

This study tests a combination of three treatments—chemotherapy infused into the liver (FOLFOX-HAIC), a targeted drug (lenvatinib), and an immunotherapy (tislelizumab)—in 38 adults with advanced liver cancer that has spread to the main portal vein. The goal is to shrink the tumor…

This study tests a new drug combination for people with advanced liver cancer that cannot be surgically removed. Participants will receive two immunotherapy drugs (adebrelimab and low-dose bevacizumab) along with a two-step procedure that delivers chemotherapy directly to the liv…

This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib) and a liver-directed procedure (TACE) in 41 people with advanced hepatocellular carcinoma, a type of liver cancer. The goal is to see if this mix can dela…

This study tests whether adding the experimental drug fostrox to the standard drug lenvatinib can shrink tumors better than lenvatinib alone in people with advanced liver cancer that got worse after immunotherapy. About 80 adults will take pills daily or in cycles until their can…

This early-phase study tests a new drug, CRPA1A2, that helps the immune system attack cancer cells. It is for people with certain advanced solid tumors (like lung, esophagus, head and neck, or liver cancer) who have a specific genetic marker (HLA-A*02:01 and MAGE-A1). The main go…

This study looks at 120 adults with advanced hepatitis B-related liver cancer who are starting immunotherapy. It compares two antiviral strategies: taking TAF alone versus taking both ETV and TAF. The goal is to see which approach helps people live longer and better controls the …

This study looks at 280 adults with liver cancer that has spread outside the liver. It compares standard drug therapy alone versus surgery to remove the main liver tumor followed by the same drug therapy. The goal is to see if adding surgery helps people live longer.

This study tests a new drug combination (SH006 injection) against a standard treatment (regorafenib) for people with advanced liver cancer that has not responded to previous immunotherapy. About 120 adults aged 18-75 will participate. The goal is to see if the new combo can slow …

This study tests whether adding a liver-directed chemotherapy infusion (HAIC) to standard oral and immune-boosting drugs helps people with advanced liver cancer that has spread into major blood vessels or bile ducts. About 150 adults will receive either the triple combo or just t…

This study tests the drug cabozantinib in 60 adults with advanced liver cancer that worsened after initial immunotherapy. The goal is to see if cabozantinib can stop or slow tumor growth for at least 6 months. Researchers will also look for blood and tissue markers that predict r…

This study tests a combination of two drugs (Benmelstobart and Anlotinib) plus targeted radiation (SBRT) in 29 adults with liver cancer that has spread to a few spots and stopped responding to initial therapy. The goal is to see if this triple therapy can control the cancer longe…

This study tests a two-step approach for people with liver cancer that is too advanced for standard transplant criteria but still removable by surgery. First, patients receive chemoembolization (TACE) plus an immunotherapy drug (QL1706) to shrink the tumor before surgery. After s…

This study tests two oral drugs, lenvatinib and regorafenib, in people with advanced liver cancer that worsened after initial immunotherapy. The goal is to see how well these drugs control tumor growth and extend life. About 146 adults with varying liver function will take the me…

This study tests whether adding a traditional Chinese herbal formula (Fufang Biejiaruangan) to standard antiviral therapy can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis. About 1,034 high-risk adults (ages 18-65) will be randomly assig…

This study tests a new drug called BB102 for people with advanced liver cancer that has not responded to other treatments. The drug targets a specific protein (FGF19) found in some liver cancers. About 60 adults will take part to see if the drug can shrink tumors and how safe it …

This study looks at people with liver cancer that has spread to a few spots outside the liver. All participants first get a combination of two drugs (sintilimab and lenvatinib). Those whose cancer is controlled are then randomly assigned to either continue the drugs alone or also…

This study is testing a new blood test that looks for specific DNA changes to see if liver cancer has come back after treatment. About 162 adults who have had or will have surgery, transplant, or other procedures for liver cancer will give blood samples before and after treatment…

This study tests a drug called nanocrystalline megestrol acetate to see if it can help prevent weight loss and improve appetite in people with advanced liver cancer who are already receiving standard treatments. About 88 participants will be randomly assigned to receive either th…

This study tests whether ondansetron, a drug typically used for nausea, can lower the risk and severity of side effects from immunotherapy in people with liver cancer. About 134 patients will receive ondansetron alongside their standard cancer treatment. The goal is to see if thi…

This study tests whether artificial intelligence (AI) can help doctors decide between two common treatments for early-stage liver cancer: surgery or microwave ablation. The AI will analyze ultrasound and MRI scans to predict which patients are likely to have their cancer return w…

This study will enroll 66 adults with liver cancer who are scheduled for either TACE or microwave ablation. Researchers will use CT scans to measure tumor volume before and after treatment to see if this method can better assess how well the therapy worked. The goal is to improve…

This study is testing whether certain substances in the blood can help doctors predict and monitor how well liver cancer responds to a standard treatment called TACE. About 60 adults with liver cancer will give blood samples before and after TACE, and the results will be compared…

This study aims to build an AI tool that analyzes standard tissue images from liver cancer patients after surgery. The goal is to predict who will benefit from additional treatments like chemotherapy or targeted drugs. Researchers will use data from 1,000 patients across multiple…

This study aims to understand why some liver cancer patients respond better to combination treatments than others. Researchers will analyze real-world medical records from 2,000 patients who received a combination of localized and drug-based therapies. The goal is to identify pat…